FDA Briefing Docs: Preclinical Cancer a Worry for Isis Drug
By Randy Osborne
Wednesday, October 17, 2012
Unexpected news for investors cropped up in briefing documents posted online by the FDA about Isis Pharmaceuticals Inc.'s lead cholesterol-lowering, antisense candidate Kynamro (mipomersen), and shares of the company took a daylong dive Tuesday as hopes for a positive vote weakened.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.